Advanced search

Vol 70, No 3 (2019)
Review paper
Published online: 2019-06-30

open access

View PDF Download PDF file
Page views 5650
Article views/downloads 3357
Get Citation

Connect on Social Media

Connect on Social Media

Hypophysitis — new insights into diagnosis and treatment

Łukasz Kluczyński1, Aleksandra Gilis-Januszewska12, Damian Rogoziński1, Jacek Pantofliński1, Alicja Hubalewska-Dydejczyk12
DOI: 10.5603/EP.a2019.0015
Pubmed: 31290557
Endokrynol Pol 2019;70(3):260-269.

Abstract

Hypophysitis is a broad term used to describe conditions leading to inflammation of the pituitary gland and the pituitary stalk. It may develop as a primary condition or secondary to other diseases. Hypophysitis is classified based on aetiological, anatomical, and histological criteria. Clinical symptoms result from enlargement of the pituitary gland, hormonal deficiencies, diabetes insipidus, and hyperprolactinemia. Histopathological verification of tissue samples from a pituitary biopsy remains the gold standard in diagnosing hypophysitis. However, due to the invasiveness and risk of the procedure it is rarely performed. The diagnosis is based mainly on clinical presentation, laboratory tests, and imaging. The rarity of the disease and the deficit in reliable data result in a lack of clear guidelines in the treatment of hypophysitis. The basic therapy relies on hormonal replacement. High doses of steroids are the first-line treatment of symptoms caused by mass effect in sella and compression of surrounding structures. In steroid-resistant patients or in cases of inacceptable sides effects, treatment with other immunosuppressant drugs was administered with success. The course of the disease varies: some patients present remission, in other cases hypophysitis leads to fibrosis and atrophy of the pituitary gland, which is reflected in persistent hormonal deficiencies and images of an empty sella. The objective of this article is to present the most important information: the epidemiology, clinical image, diagnostic procedures, and treatment of primary hypophysitis, in order to allow better understanding of this disease and implementation of proper management. Posttraumatic and immunotherapyrelated hypophysitis are also briefly characterised.

Keywords: hypophysitispituitary insufficiencyhypopituitarismdiabetes insipiduspituitary stalk lesion

Article available in PDF format

View PDF Download PDF file

References

  1. Simmonds M. Über Hypophysischwund mit tödlichem ausgang. Dtsch Med Wochenschr. 1914; 40(7): 322–323.
  2. Gliński LKZ. Z kazuistyki zmian anatomo-patologicznych w przysadce mózgowej. Prz Lek. 1913; 52: 13–14.
  3. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev. 2005; 26(5): 599–614.
    CrossRefPubMed
  4. Prete A, Salvatori R. Hypophysitis. Endotext [Internet]. South Dartmouth 2018. https://www.ncbi.nlm.nih.gov/books/NBK519842/.
  5. McKeel DW. Primary hypothyroidism and hypopituitarism in a young woman. Am J Med. 1984; 77(2): 319–330.
    PubMed
  6. Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg. 2001; 15(3): 242–5, discussion 245.
    CrossRefPubMed
  7. Sautner D, Saeger W, Lüdecke DK, et al. Hypophysitis in surgical and autoptical specimens. Acta Neuropathol. 1995; 90(6): 637–644.
    CrossRefPubMed
  8. De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab. 2005; 19(1): 67–84.
    CrossRefPubMed
  9. Nakamura Y, Okada H, Wada Y, et al. Lymphocytic hypophysitis: its expanding features. J Endocrinol Invest. 2001; 24(4): 262–267.
    CrossRefPubMed
  10. Barbaro D, Loni G. Lymphocytic hypophysitis and autoimmune thyroid disease. J Endocrinol Invest. 2000; 23(5): 339–340.
    CrossRefPubMed
  11. Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. 2003; 74(1): 9–33.
    PubMed
  12. Weetman AP. Non-thyroid autoantibodies in autoimmune thyroid disease. Best Pract Res Clin Endocrinol Metab. 2005; 19(1): 17–32.
    CrossRefPubMed
  13. Bellastella A, Bizzarro A, Coronella C, et al. Lymphocytic hypophysitis: a rare or underestimated disease? Eur J Endocrinol. 2003; 149(5): 363–376.
    CrossRefPubMed
  14. Heaney AP, Sumerel B, Rajalingam R, et al. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. J Clin Endocrinol Metab. 2015; 100(11): 4092–4097.
    CrossRefPubMed
  15. Goudie RB, Pinkerton PH, Goudie RB, et al. Anterior hypophysitis and hashimoto's disease in a young woman. J Pathol Bacteriol. 1962; 83(2): 584–585.
    CrossRefPubMed
  16. Caturegli P, Lupi I, Landek-Salgado M, et al. Pituitary autoimmunity: 30 years later. Autoimmun Rev. 2008; 7(8): 631–637.
    CrossRefPubMed
  17. Simmonds M, Simmonds M, Simmonds M. Über das Vorkommen von Riesenzellen in der Hypophyse. Virchows Archiv Path Anat Physiol Klin Med. 1917; 223(3): 281–290.
    CrossRef
  18. Taylon C, Duff TA, Taylon C, et al. Giant cell granuloma involving the pituitary gland. Case report. J Neurosurg. 1980; 52(4): 584–587.
    CrossRefPubMed
  19. Hunn BHM, Martin WG, Simpson S, et al. Idiopathic granulomatous hypophysitis: a systematic review of 82 cases in the literature. Pituitary. 2014; 17(4): 357–365.
    CrossRefPubMed
  20. Kleinschmidt-DeMasters BK, Lillehei KO, Hankinson TC, et al. Review of xanthomatous lesions of the sella. Brain Pathol. 2017; 27(3): 377–395.
    CrossRefPubMed
  21. Duan K, Asa SL, Winer D, et al. Xanthomatous Hypophysitis Is Associated with Ruptured Rathke's Cleft Cyst. Endocr Pathol. 2017; 28(1): 83–90.
    CrossRefPubMed
  22. Bernreuther C, Illies C, Flitsch J, et al. IgG4-related hypophysitis is highly prevalent among cases of histologically confirmed hypophysitis. Brain Pathol. 2017; 27(6): 839–845.
    CrossRefPubMed
  23. Kuruma S, Kamisawa T, Tabata T, et al. Allergen-specific IgE Antibody Serologic Assays in Patients with Autoimmune Pancreatitis. Intern Med. 2014; 53(6): 541–543.
    CrossRefPubMed
  24. Stone JH, Zen Y, Deshpande V, et al. IgG4-related disease. N Engl J Med. 2012; 366(6): 539–551.
    CrossRefPubMed
  25. Weindorf SC, Frederiksen JK, Weindorf SC, et al. IgG4-Related Disease: A Reminder for Practicing Pathologists. Arch Pathol Lab Med. 2017; 141(11): 1476–1483.
    CrossRefPubMed
  26. Khosroshahi A, Wallace ZS, Crowe JL, et al. Second International Symposium on IgG4-Related Disease, Second International Symposium on IgG4-Related Disease, Second International Symposium on IgG4-Related Disease. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015; 67(7): 1688–1699.
    CrossRefPubMed
  27. Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford). 2015; 54(11): 1982–1990.
    CrossRefPubMed
  28. Bando H, Iguchi G, Fukuoka H, et al. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol. 2014; 170(2): 161–172.
    CrossRefPubMed
  29. Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab. 2011; 96(7): 1971–1980.
    CrossRefPubMed
  30. Gutenberg A, Caturegli P, Metz I, et al. Necrotizing infundibulo-hypophysitis: an entity too rare to be true? Pituitary. 2012; 15(2): 202–208.
    CrossRefPubMed
  31. Fukuoka H. Hypophysitis. Endocrinol Metab Clin North Am. 2015; 44(1): 143–149.
    CrossRefPubMed
  32. Suzuki K, Izawa N, Nakamura T, et al. Lymphocytic Hypophysitis Accompanied by Aseptic Meningitis Mimics Subacute Meningoencephalitis. Intern Med. 2011; 50(18): 2025–2030.
    CrossRefPubMed
  33. Brandes JC, Cerletty JM, Brandes JC, et al. Pregnancy in lymphocytic hypophysitis: case report and review. Wis Med J. 1989; 88(11): 29–32.
    PubMed
  34. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol. 1998; 22(6): 457–470.
    CrossRefPubMed
  35. Tsur A, Leibowitz G, Samueloff A, et al. Successful pregnancy in a patient with preexisting lymphocytic hypophysitis. Acta Obstet Gynecol Scan. 1996; 75(8): 772–774.
    CrossRef
  36. Gagneja H, Arafah B, Taylor HC, et al. Histologically proven lymphocytic hypophysitis: spontaneous resolution and subsequent pregnancy. Mayo Clin Proc. 1999; 74(2): 150–154.
    CrossRefPubMed
  37. Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med. 1988; 85(2): 217–220.
    CrossRefPubMed
  38. Asa SL, Penz G, Kovacs K, et al. Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med. 1982; 106(7): 360–363.
    PubMed
  39. Pouplard-Barthelaix A, Lepinard V, Luxembourger L, et al. Circulating pituitary autoantibodies against cells secreting luteinising and follicle stimulating hormones in children with cryptorchidism. Lancet. 1984; 2(8403): 631–632.
    PubMed
  40. Elias KA, Weiner RI. Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA. 1984; 81(14): 4549–4553.
    CrossRefPubMed
  41. O'Dwyer DT, Clifton V, Hall A, et al. Pituitary autoantibodies in lymphocytic hypophysitis target both gamma- and alpha-enolase — a link with pregnancy? Arch Physiol Biochem. 2002; 110(1-2): 94–98.
    CrossRefPubMed
  42. Bensing S, Fetissov SO, Mulder J, et al. Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1. Proc Natl Acad Sci USA. 2007; 104(3): 949–954.
    CrossRefPubMed
  43. Landek-Salgado MA, Rose NR, Caturegli P. Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1. J Autoimmun. 2012; 38(2-3): J88–J96.
    CrossRefPubMed
  44. Honegger J, Schlaffer S, Menzel C, et al. Pituitary Working Group of the German Society of Endocrinology, Pituitary Working Group of the German Society of Endocrinology, Pituitary Working Group of the German Society of Endocrinology. Diagnosis of Primary Hypophysitis in Germany. J Clin Endocrinol Metab. 2015; 100(10): 3841–3849.
    CrossRefPubMed
  45. Bellastella G, Maiorino MI, Bizzarro A, et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary. 2016; 19(6): 625–642.
    CrossRefPubMed
  46. Cosman F, Post K, Holub D, et al. Lymphocytic Hypophysitis. Report of 3 New Cases and Review of the Literature. Medicine. 1989; 68(4): 240.
    CrossRefPubMed
  47. Beressi N, Beressi JP, Cohen R, et al. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999; 150(4): 327–341.
    PubMed
  48. Lipscombe L, Asa S, Ezzat S, et al. Management of Lesions of the Pituitary Stalk and Hypothalamus. The Endocrinologist. 2003; 13(1): 38–51.
    CrossRef
  49. Pestell RG, Best JD, Alford FP, et al. Lymphocytic hypophysitis. The clinical spectrum of the disorder and evidence for an autoimmune pathogenesis. Clin Endocrinol (Oxf). 1990; 33(4): 457–466.
    PubMed
  50. Levy MJ, Jäger HR, Powell M, et al. Pituitary volume and headache: size is not everything. Arch Neurol. 2004; 61(5): 721–725.
    CrossRefPubMed
  51. Supler M, Mickle J. Lymphocytic hypophysitis: report of a case in a man with cavernous sinus involvement. Surgical Neurology. 1992; 37(6): 472–476.
    CrossRefPubMed
  52. Tubridy N, Saunders D, Thom M, et al. Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement. J Neurol Neurosurg Psychiatry. 2001; 71(6): 798–801.
    CrossRefPubMed
  53. Kartal I, Yarman S, Tanakol R, et al. Lymphocytic panhypophysitis in a young man with involvement of the cavernous sinus and clivus. Pituitary. 2007; 10(1): 75–80.
    CrossRefPubMed
  54. Joshi MN, Whitelaw BC, Carroll PV, et al. Mechanisms in endocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018; 179(3): R151–R163.
    CrossRefPubMed
  55. Ikeda J, Kuratsu J, Miura M, et al. Lymphocytic adenohypophysitis accompanying occlusion of bilateral internal carotid arteries — case report. Neurol Med Chir (Tokyo). 1990; 30(5): 346–349.
    CrossRefPubMed
  56. Wu GF, Balcer LJ. Endocrine and metabolic deficiency. Ophthalmol Clin North Am. 2004; 17(3): 427–34, vii.
    CrossRefPubMed
  57. Crock P. Lymphocytic hypophysitis. Curr Opin Endocrinol Diab Obes. 1997; 4(2): 115–123.
    CrossRef
  58. Cheung CC, Ezzat S, Smyth HS, et al. The spectrum and significance of primary hypophysitis. J Clin Endocrinol Metab. 2001; 86(3): 1048–1053.
    CrossRefPubMed
  59. Falorni A, Minarelli V, Bartoloni E, et al. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014; 13(4-5): 412–416.
    CrossRefPubMed
  60. Nagai Y, Ieki Y, Ohsawa K, et al. Simultaneously found transient hypothyroidism due to hashimoto's thyroiditis, autoimmune hepatitis and isolated ACTH deficiency after cessation of glucocorticoid administration. Endocrine Journal. 1997; 44(3): 453–458.
    CrossRefPubMed
  61. Breen T, Post K, Wardlaw S. Lymphocytic hypophysitis. The Endocrinologist. 2004; 14(1): 13–18.
    CrossRef
  62. Guay AT, Agnello US, Freidberg SR, et al. Lymphocytic adenohypophysitis in a man. Can J Neurol Sci. 1988; 15(4): 439–440.
    PubMed
  63. De Bellis A, Bellastella G, Colella C, et al. Use of serum pituitary antibodies to improve the diagnosis of hypophysitis. Expert Rev Endocrinol Metab. 2014; 9(5): 465–476.
    CrossRefPubMed
  64. Hashimoto K, Takao T, Makino S. Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Endocr J. 1997; 44(1): 1–10.
    CrossRefPubMed
  65. Molitch ME. Endocrine emergencies in pregnancy. Baillieres Clin Endocrinol Metab. 1992; 6(1): 167–191.
    CrossRefPubMed
  66. Prager D, Braunstein GD. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am. 1995; 24(1): 1–14.
    CrossRefPubMed
  67. Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society, Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2): 273–288.
    CrossRefPubMed
  68. Shelly S, Boaz M, Orbach H, et al. Prolactin and autoimmunity. Autoimmun Rev. 2012; 11(6-7): A465–A470.
    CrossRefPubMed
  69. De Bellis A, Bizzarro A, Perrino S, et al. Characterization of antipituitary antibodies targeting pituitary hormone-secreting cells in idiopathic growth hormone deficiency and autoimmune endocrine diseases. Clin Endocrinol (Oxf). 2005; 63(1): 45–49.
    CrossRefPubMed
  70. Koshiyama H, Sato H, Yorita S, et al. Lymphocytic Hypophysitis Presenting with Diabetes Insipidus: Case Report and Literature Review. Endocrine Journal. 1994; 41(1): 93–97.
    CrossRefPubMed
  71. Ohta M, Kimura T, Ota K, et al. Glucocorticoid-Induced Central Diabetes Insipidus in a Case of Malignant Lymphoma. Tohoku J Exp Med. 1991; 163(4): 245–254.
    CrossRefPubMed
  72. Gutenberg A, Hans V, Puchner MJA, et al. Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol. 2006; 155(1): 101–107.
    CrossRefPubMed
  73. Shikuma J, Kan K, Ito R, et al. Critical review of IgG4-related hypophysitis. Pituitary. 2017; 20(2): 282–291.
    CrossRefPubMed
  74. Kalra AA, Riel-Romero RM, Gonzalez-Toledo E. Lymphocytic hypophysitis in children: a novel presentation and literature review. J Child Neurol. 2011; 26(1): 87–94.
    CrossRefPubMed
  75. Gan, HW, Bulwer C, Spoudeas H. Pituitary and hypothalamic tumor syndromes in childhood. Endotext [Internet]. South Dartmouth 2017. https://www.ncbi.nlm.nih.gov/books/NBK279153/.
  76. Fehn M, Sommer C, Ludecke DK, et al. Lymphocytic Hypophysitis: Light and Electron Microscopic Findings and Correlation to Clinical Appearance. Endocr Pathol. 1998; 9(1): 71–78.
    PubMed
  77. Sautner D, Saeger W, Lüdecke DK, et al. Hypophysitis in surgical and autoptical specimens. Acta Neuropathol. 1995; 90(6): 637–644.
    CrossRefPubMed
  78. Krysiak R, Okopień B, Herman ZS. [Hypophysitis]. Przegl Lek. 2007; 64(7–8): 515–520.
    PubMed
  79. Saiwai S, Inoue Y, Ishihara T, et al. Lymphocytic adenohypophysitis: skull radiographs and MRI. Neuroradiology. 1998; 40(2): 114–120.
    CrossRefPubMed
  80. Sotoudeh H, Yazdi HR. A review on dural tail sign. World J Radiol. 2010; 2(5): 188–192.
    CrossRefPubMed
  81. Turcu AF, Erickson BJ, Lin E, et al. Pituitary stalk lesions: the Mayo Clinic experience. J Clin Endocrinol Metab. 2013; 98(5): 1812–1818.
    CrossRefPubMed
  82. Gao H, Gu YY, Qiu Mc. Autoimmune hypophysitis may eventually become empty sella. Neuro Endocrinol Lett. 2013; 34(2): 102–106.
    PubMed
  83. Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol. 2009; 30(9): 1766–1772.
    CrossRefPubMed
  84. Crock PA. Cytosolic autoantigens in lymphocytic hypophysitis. J Clin Endocrinol Metab. 1998; 83(2): 609–618.
    CrossRefPubMed
  85. Bensing S, Hulting AL, Höög A, et al. Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest. 2007; 30(2): 153–162.
    CrossRefPubMed
  86. Tanaka S, Tatsumi Ki, Kimura M, et al. Detection of autoantibodies against the pituitary-specific proteins in patients with lymphocytic hypophysitis. Eur J Endocrinol. 2002; 147(6): 767–775.
    PubMed
  87. Allix I, Rohmer V. Hypophysitis in 2014. Ann Endocrinol (Paris). 2015; 76(5): 585–594.
    CrossRefPubMed
  88. Iwama S, Sugimura Y, Kiyota A, et al. Rabphilin-3A as a Targeted Autoantigen in Lymphocytic Infundibulo-neurohypophysitis. J Clin Endocrinol Metab. 2015; 100(7): E946–E954.
    CrossRefPubMed
  89. Faje A. Hypophysitis: Evaluation and Management. Clin Diabetes Endocrinol. 2016; 2(1): 15.
    CrossRefPubMed
  90. De Bellis A, Sinisi AA, Pane E, et al. Italian Autoimmune Hypophysitis Network Group. Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. J Clin Endocrinol Metab. 2012; 97(10): 3684–3690.
    CrossRefPubMed
  91. De Bellis A, Colao A, Di Salle F, et al. A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab. 1999; 84(9): 3047–3051.
    CrossRefPubMed
  92. Thapar K, Kohata T, Laws ER. Parasellar lesions other than pituitary adenomas. In: Powell MP, Lightman SL. ed. Management of Pituitary Tumor. The Clinician’s Practical Guide. 2nd ed. Humana Press, New Jersey 2003: 231–286.
  93. Keleştimur F. Sheehan's Syndrome. Pituitary. 2003; 6(4): 181–188.
    CrossRefPubMed
  94. De Bellis A, Kelestimur F, Sinisi AA, et al. Anti-hypothalamus and anti-pituitary antibodies may contribute to perpetuate the hypopituitarism in patients with Sheehan's syndrome. Eur J Endocrinol. 2008; 158(2): 147–152.
    CrossRefPubMed
  95. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014; 383(9935): 2152–2167.
    CrossRefPubMed
  96. Hannoush ZC, Weiss RE. Hypopituitarism: emergencies. Endotext [Internet]. South Dartmouth 2018. https://www.ncbi.nlm.nih.gov/books/NBK279063/.
  97. Khare S, Jagtap VS, Budyal SR, et al. Primary (autoimmune) hypophysitis: a single centre experience. Pituitary. 2015; 18(1): 16–22.
    CrossRefPubMed
  98. Huguet I, Clayton R. Pituitary-hypothalamic tumor syndromes: adults. Endotext [Internet]. South Dartmouth 2015. https://www.ncbi.nlm.nih.gov/books/NBK278946/.
  99. Caputo C, Bazargan A, McKelvie PA, et al. Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy. Pituitary. 2014; 17(3): 251–256.
    CrossRefPubMed
  100. Schreckinger M, Francis T, Rajah G, et al. Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg. 2012; 116(6): 1318–1323.
    CrossRefPubMed
  101. Krysiak R, Samborek M, Stojko R. Anti-inflammatory effects of bromocriptine in a patient with autoimmune polyglandular syndrome type 2. Neuro Endocrinol Lett. 2014; 35(3): 179–182.
    PubMed
  102. Hypophystis Research Centre at Johns Hopkins Medical Institutions. http://pathology.jhu.edu/hypophysitis/.
  103. Lupi I, Manetti L, Raffaelli V, et al. Diagnosis and treatment of autoimmune hypophysitis: a short review. J Endocrinol Invest. 2011; 34(8): e245–e252.
    CrossRefPubMed
  104. Lupi I, Cosottini M, Caturegli P, et al. Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. Eur J Endocrinol. 2017; 177(2): 127–135.
    CrossRefPubMed
  105. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4): 1361–1375.
    CrossRefPubMed
  106. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.
    CrossRefPubMed
  107. Król A, Gawlik T, Jarząb B. Endocrine complications of cancer immunotherapy. Endokrynol Pol. 2018; 69(6): 722–733.
    CrossRefPubMed
  108. Min Le, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015; 21(4): 749–755.
    CrossRefPubMed
  109. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014; 99(11): 4078–4085.
    CrossRefPubMed
  110. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014; 6(230): 230ra45.
    CrossRefPubMed
  111. Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015; 112(19): 6140–6145.
    CrossRefPubMed
  112. Laurent S, Queirolo P, Boero S, et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med. 2013; 11: 108.
    CrossRefPubMed
  113. De Sousa SMC, Sheriff N, Tran CH, et al. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018; 21(3): 274–282.
    CrossRefPubMed
  114. Chodakiewitz Y, Brown S, Boxerman JL, et al. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg. 2014; 125: 125–130.
    CrossRefPubMed
  115. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016; 19(1): 82–92.
    CrossRefPubMed
  116. Scott ES, Long GV, Guminski A, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018; 178(2): 173–180.
    CrossRefPubMed
  117. Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016; 186(12): 3225–3235.
    CrossRefPubMed
  118. Tanriverdi F, De Bellis A, Bizzarro A, et al. Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity? Eur J Endocrinol. 2008; 159(1): 7–13.
    CrossRefPubMed
  119. Tanriverdi F, Unluhizarci K, Kelestrimur F. Persistent neuroinflammation may be involved in the pathogenesis of traumatic brain injury (TBI)-induced hypopituitarism: potential genetic and autoimmune factors. J Neurotrauma. 2010; 27(2): 301–302.
    CrossRefPubMed
  120. Tanriverdi F, De Bellis A, Ulutabanca H, et al. A five year prospective investigation of anterior pituitary function after traumatic brain injury: is hypopituitarism long-term after head trauma associated with autoimmunity? J Neurotrauma. 2013; 30(16): 1426–1433.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note